Global Pancreatic Beta-Cell Protection 麻豆原创 Research Report 2023

Publication ID:

PB510234318

Publication Date:

October 3, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Beta Cells. Beta cells are unique cells in the pancreas that produce, store and release the hormone insulin.
The global Pancreatic Beta-Cell Protection market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pancreatic Beta-Cell Protection market research.
Key companies engaged in the Pancreatic Beta-Cell Protection industry include ViaCyte, PharmaCyte Biotech, Boehringer Ingelheim, GalaxoSmithKline, Beta-Cell NV, Novartis, Janssen Research & Development, Pfizer Inc and BioLineRx, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Pancreatic Beta-Cell Protection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Pancreatic Beta-Cell Protection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Pancreatic Beta-Cell Protection market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
ViaCyte
PharmaCyte Biotech
Boehringer Ingelheim
GalaxoSmithKline
Beta-Cell NV
Novartis
Janssen Research & Development
Pfizer Inc
BioLineRx
Genentech
Novo Nordisk
Sanofi
Osiris Therapeutics
Beta-O2 Technologies Ltd
Transition Therapeutics
Segment by Type
Stem Cell Based
Gene Therapies
RNA Based Therapies
Monoclonal Antibodies (MAbs)
Phytotherapy
Segment by Application
Hospital
Medical Research Laboratory
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pancreatic Beta-Cell Protection report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Pancreatic Beta-Cell Protection 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Stem Cell Based
1.2.3 Gene Therapies
1.2.4 RNA Based Therapies
1.2.5 Monoclonal Antibodies (MAbs)
1.2.6 Phytotherapy
1.3 麻豆原创 by Application
1.3.1 Global Pancreatic Beta-Cell Protection 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Medical Research Laboratory
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pancreatic Beta-Cell Protection 麻豆原创 Perspective (2018-2029)
2.2 Pancreatic Beta-Cell Protection Growth Trends by Region
2.2.1 Global Pancreatic Beta-Cell Protection 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Pancreatic Beta-Cell Protection Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Pancreatic Beta-Cell Protection Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Pancreatic Beta-Cell Protection 麻豆原创 Dynamics
2.3.1 Pancreatic Beta-Cell Protection Industry Trends
2.3.2 Pancreatic Beta-Cell Protection 麻豆原创 Drivers
2.3.3 Pancreatic Beta-Cell Protection 麻豆原创 Challenges
2.3.4 Pancreatic Beta-Cell Protection 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pancreatic Beta-Cell Protection Players by Revenue
3.1.1 Global Top Pancreatic Beta-Cell Protection Players by Revenue (2018-2023)
3.1.2 Global Pancreatic Beta-Cell Protection Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Pancreatic Beta-Cell Protection 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pancreatic Beta-Cell Protection Revenue
3.4 Global Pancreatic Beta-Cell Protection 麻豆原创 Concentration Ratio
3.4.1 Global Pancreatic Beta-Cell Protection 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pancreatic Beta-Cell Protection Revenue in 2022
3.5 Pancreatic Beta-Cell Protection Key Players Head office and Area Served
3.6 Key Players Pancreatic Beta-Cell Protection Product Solution and Service
3.7 Date of Enter into Pancreatic Beta-Cell Protection 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Pancreatic Beta-Cell Protection Breakdown Data by Type
4.1 Global Pancreatic Beta-Cell Protection Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Pancreatic Beta-Cell Protection Forecasted 麻豆原创 Size by Type (2024-2029)
5 Pancreatic Beta-Cell Protection Breakdown Data by Application
5.1 Global Pancreatic Beta-Cell Protection Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Pancreatic Beta-Cell Protection Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Pancreatic Beta-Cell Protection 麻豆原创 Size (2018-2029)
6.2 North America Pancreatic Beta-Cell Protection 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Pancreatic Beta-Cell Protection 麻豆原创 Size by Country (2018-2023)
6.4 North America Pancreatic Beta-Cell Protection 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pancreatic Beta-Cell Protection 麻豆原创 Size (2018-2029)
7.2 Europe Pancreatic Beta-Cell Protection 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Pancreatic Beta-Cell Protection 麻豆原创 Size by Country (2018-2023)
7.4 Europe Pancreatic Beta-Cell Protection 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pancreatic Beta-Cell Protection 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Pancreatic Beta-Cell Protection 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Pancreatic Beta-Cell Protection 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Pancreatic Beta-Cell Protection 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pancreatic Beta-Cell Protection 麻豆原创 Size (2018-2029)
9.2 Latin America Pancreatic Beta-Cell Protection 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Pancreatic Beta-Cell Protection 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Pancreatic Beta-Cell Protection 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pancreatic Beta-Cell Protection 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Pancreatic Beta-Cell Protection 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Pancreatic Beta-Cell Protection 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Pancreatic Beta-Cell Protection 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 ViaCyte
11.1.1 ViaCyte Company Detail
11.1.2 ViaCyte Business Overview
11.1.3 ViaCyte Pancreatic Beta-Cell Protection Introduction
11.1.4 ViaCyte Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.1.5 ViaCyte Recent Development
11.2 PharmaCyte Biotech
11.2.1 PharmaCyte Biotech Company Detail
11.2.2 PharmaCyte Biotech Business Overview
11.2.3 PharmaCyte Biotech Pancreatic Beta-Cell Protection Introduction
11.2.4 PharmaCyte Biotech Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.2.5 PharmaCyte Biotech Recent Development
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Detail
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Pancreatic Beta-Cell Protection Introduction
11.3.4 Boehringer Ingelheim Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.3.5 Boehringer Ingelheim Recent Development
11.4 GalaxoSmithKline
11.4.1 GalaxoSmithKline Company Detail
11.4.2 GalaxoSmithKline Business Overview
11.4.3 GalaxoSmithKline Pancreatic Beta-Cell Protection Introduction
11.4.4 GalaxoSmithKline Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.4.5 GalaxoSmithKline Recent Development
11.5 Beta-Cell NV
11.5.1 Beta-Cell NV Company Detail
11.5.2 Beta-Cell NV Business Overview
11.5.3 Beta-Cell NV Pancreatic Beta-Cell Protection Introduction
11.5.4 Beta-Cell NV Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.5.5 Beta-Cell NV Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Pancreatic Beta-Cell Protection Introduction
11.6.4 Novartis Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.6.5 Novartis Recent Development
11.7 Janssen Research & Development
11.7.1 Janssen Research & Development Company Detail
11.7.2 Janssen Research & Development Business Overview
11.7.3 Janssen Research & Development Pancreatic Beta-Cell Protection Introduction
11.7.4 Janssen Research & Development Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.7.5 Janssen Research & Development Recent Development
11.8 Pfizer Inc
11.8.1 Pfizer Inc Company Detail
11.8.2 Pfizer Inc Business Overview
11.8.3 Pfizer Inc Pancreatic Beta-Cell Protection Introduction
11.8.4 Pfizer Inc Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.8.5 Pfizer Inc Recent Development
11.9 BioLineRx
11.9.1 BioLineRx Company Detail
11.9.2 BioLineRx Business Overview
11.9.3 BioLineRx Pancreatic Beta-Cell Protection Introduction
11.9.4 BioLineRx Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.9.5 BioLineRx Recent Development
11.10 Genentech
11.10.1 Genentech Company Detail
11.10.2 Genentech Business Overview
11.10.3 Genentech Pancreatic Beta-Cell Protection Introduction
11.10.4 Genentech Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.10.5 Genentech Recent Development
11.11 Novo Nordisk
11.11.1 Novo Nordisk Company Detail
11.11.2 Novo Nordisk Business Overview
11.11.3 Novo Nordisk Pancreatic Beta-Cell Protection Introduction
11.11.4 Novo Nordisk Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.11.5 Novo Nordisk Recent Development
11.12 Sanofi
11.12.1 Sanofi Company Detail
11.12.2 Sanofi Business Overview
11.12.3 Sanofi Pancreatic Beta-Cell Protection Introduction
11.12.4 Sanofi Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.12.5 Sanofi Recent Development
11.13 Osiris Therapeutics
11.13.1 Osiris Therapeutics Company Detail
11.13.2 Osiris Therapeutics Business Overview
11.13.3 Osiris Therapeutics Pancreatic Beta-Cell Protection Introduction
11.13.4 Osiris Therapeutics Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.13.5 Osiris Therapeutics Recent Development
11.14 Beta-O2 Technologies Ltd
11.14.1 Beta-O2 Technologies Ltd Company Detail
11.14.2 Beta-O2 Technologies Ltd Business Overview
11.14.3 Beta-O2 Technologies Ltd Pancreatic Beta-Cell Protection Introduction
11.14.4 Beta-O2 Technologies Ltd Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.14.5 Beta-O2 Technologies Ltd Recent Development
11.15 Transition Therapeutics
11.15.1 Transition Therapeutics Company Detail
11.15.2 Transition Therapeutics Business Overview
11.15.3 Transition Therapeutics Pancreatic Beta-Cell Protection Introduction
11.15.4 Transition Therapeutics Revenue in Pancreatic Beta-Cell Protection Business (2018-2023)
11.15.5 Transition Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

ViaCyte
PharmaCyte Biotech
Boehringer Ingelheim
GalaxoSmithKline
Beta-Cell NV
Novartis
Janssen Research & Development
Pfizer Inc
BioLineRx
Genentech
Novo Nordisk
Sanofi
Osiris Therapeutics
Beta-O2 Technologies Ltd
Transition Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.